Trimer-Tag
Clover Reports Phase 2 Data for RSV/hMPV/PIV3 Vaccines
Clover Biopharmaceuticals, Ltd. (HKEX: 02197) announced on September 6 positive preliminary Phase 2 data from a trial in Australia testing two combination vaccine candidates, SCB-1022 (targeting RSV and hMPV) and SCB-1033 (targeting RSV, hMPV, and PIV3), in adults ages 60 to 85. The results are notable partly because two of the three viruses involved, human…
